MedTrace Logo

Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines

NCT06355219 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3932

Last updated 2024-05-21

No results posted yet for this study

Summary

The goal of this study is to compare the impact of metabolic surgery and a class of anti-diabetes medications (Glucagon-like peptide-1 receptor agonists,GLP-1 RAs) on occurrence of diseases involving small and large vessels such as heart disease, kidney disease, and disease of the retina (a part of the eye), as well as deaths.

Conditions

Sponsors & Collaborators

  • Ali Aminian

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-01
Primary Completion
2022-12-31
Completion
2024-05-20

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06355219 on ClinicalTrials.gov